Ganymed Pharmaceuticals GmbH
An der Goldgrube 12
D-55131 Mainz
Phone: +49 (0) 6131 / 1440 - 100
Fax: +49 (0) 6131 / 1440 - 114

Our mission

At Ganymed, we aim to revolutionize cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on cancer cells, but do not bind to healthy cells.

Due to this unmatched cancer-cell specificity, IMABs will be high-precision therapeutics that efficiently kill cancer cells without harming normal healthy tissues.